Associations of FGF23 with Change in Bone Mineral Density and Fracture Risk in Older Individuals

Journal of Bone and Mineral Research

Volumn 31, Issue 4, 2016, Pages 742-748

  Isakova, Tamara ^a   Cai, Xuan ^a   Lee, Jungwha ^a   Katz, Ronit ^b   Cauley, Jane A ^c   Fried, Linda F ^d   Hoofnagle, Andrew N ^b   Satterfield, Suzanne ^e   Harris, Tamara B ^f   Shlipak, Michael G ^g   Sarnak, Mark J ^h   Ix, Joachim H ⁱ  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^f NATIONAL INSTITUTE ON AGING   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h TUFTS MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bone Mineral Density; Chronic Kidney Disease; Fibroblast Growth Factor 23; Fracture

Indexed keywords

25 HYDROXYVITAMIN D; ALBUMIN; CALCIUM; CREATININE; CYSTATIN C; FIBROBLAST GROWTH FACTOR 23; LOOP DIURETIC AGENT; PARATHYROID HORMONE; PHOSPHATE; STEROID; THIAZIDE DIURETIC AGENT; FIBROBLAST GROWTH FACTOR;

AGED; ARTICLE; BONE DENSITY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; FRACTURE; GLOMERULUS FILTRATION RATE; HIP; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; UNITED STATES; BLOOD; CLINICAL TRIAL; FRACTURES, BONE; MULTICENTER STUDY; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR;

AGED; BONE DENSITY; FEMALE; FIBROBLAST GROWTH FACTORS; FOLLOW-UP STUDIES; FRACTURES, BONE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; PARATHYROID HORMONE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84952683967     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2750     Document Type: Article

References (45)

1. Magaziner J, Simonsick EM, Kashner TM, Hebel JR, Kenzora JE,. Predictors of functional recovery one year following hospital discharge for hip fracture: a prospective study. J Gerontol. 1990; 45: M101-7.
2. Lu-Yao GL, Baron JA, Barrett JA, Fisher ES,. Treatment and survival among elderly Americans with hip fractures: a population-based study. Am J Public Health. 1994; 84: 1287-91.
3. Ray NF, Chan JK, Thamer M, Melton LJ 3rd,. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997; 12: 24-35.
4. Bass E, French DD, Bradham DD,. A national perspective of Medicare expenditures for elderly veterans with hip fractures. J Am Med Dir Assoc. 2008; 9: 114-9.
5. Cosman F, de Beur SJ, LeBoff MS, et al., Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014; 25: 2359-81.
6. Wolf M,. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol. 2010; 21: 1427-35.
7. Isakova T, Wahl P, Vargas GS, et al., Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011; 79: 1370-8.
8. Ferrari SL, Bonjour JP, Rizzoli R,. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab. 2005; 90: 1519-24.
9. Shimada T, Kakitani M, Yamazaki Y, et al., Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004; 113: 561-8.
10. Shimada T, Hasegawa H, Yamazaki Y, et al., FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004; 19: 429-35.
11. Zimering MB, Caldarella FA, White KE, Econs MJ,. Persistent tumor-induced osteomalacia confirmed by elevated postoperative levels of serum fibroblast growth factor-23 and 5-year follow-up of bone density changes. Endocr Pract. 2005; 11: 108-14.
12. Bergwitz C, Collins MT, Kamath RS, Rosenberg AE,. Case records of the Massachusetts General Hospital. Case 33-2011. A 56-year-old man with hypophosphatemia. N Engl J Med. 2011; 365: 1625-35.
13. Jovanovich A, Buzkova P, Chonchol M, et al., Fibroblast growth factor 23, bone mineral density, and risk of hip fracture among older adults: the cardiovascular health study. J Clin Endocrinol Metab. 2013; 98: 3323-31.
14. Mirza MA, Karlsson MK, Mellstrom D, et al., Serum fibroblast growth factor-23 (FGF-23) and fracture risk in elderly men. J Bone Miner Res. 2011; 26: 857-64.
15. Lane NE, Parimi N, Corr M, et al., Association of serum fibroblast growth factor 23 (FGF23) and incident fractures in older men: the Osteoporotic Fractures in Men (MrOS) study. J Bone Miner Res. 2013; 28: 2325-32.
16. Manghat P, Fraser WD, Wierzbicki AS, Fogelman I, Goldsmith DJ, Hampson G,. Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int. 2010; 21: 1853-61.
17. Desjardins L, Liabeuf S, Renard C, et al., FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int. 2012; 23: 2017-25.
18. National Institute on Aging. National Institutes of Health. Health, Aging, and Body Composition (Health ABC) Study [Internet]. Bethesda (MD): National Institute on Aging; 2015 [cited 2015 Dec 13]. Available from: http://www.grc.nia.nih.gov/branches/leps/healthabc.
19. Burnett SM, Gunawardene SC, Bringhurst FR, Juppner H, Lee H, Finkelstein JS,. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res. 2006; 21: 1187-96.
20. Inker LA, Schmid CH, Tighiouart H, et al., Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012; 367: 20-9.
21. Fine JP, Gray RJ,. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94: 496-509.
22. Yamazaki Y, Okazaki R, Shibata M, et al., Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab. 2002; 87: 4957-60.
23. White KE, Evans WE, O'Riordan JLH, et al., Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000; 26: 345-8.
24. Jonsson KB, Zahradnik R, Larsson T, et al., Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003; 348: 1656-63.
25. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al., The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007; 117: 4003-8.
26. Antoniucci DM, Yamashita T, Portale AA,. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab. 2006; 91: 3144-9.
27. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB,. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003; 64: 2272-9.
28. Shigematsu T, Kazama JJ, Yamashita T, et al., Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis. 2004; 44: 250-6.
29. Gutierrez O, Isakova T, Rhee E, et al., Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005; 16: 2205-15.
30. Ix JH, Katz R, Kestenbaum BR, et al., Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol. 2012; 60: 200-7.
31. Hasegawa H, Nagano N, Urakawa I, et al., Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int. 2010; 78: 975-80.
32. Parker BD, Schurgers LJ, Brandenburg VM, et al., The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med. 2010; 152: 640-8.
33. Isakova T, Xie H, Yang W, et al., Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011; 305: 2432-9.
34. Scialla JJ, Xie H, Rahman M, et al., Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol. 2014; 25: 349-60.
35. Sitara D, Razzaque MS, Hesse M, et al., Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 2004; 23: 421-32.
36. Liu S, Tang W, Zhou J, Vierthaler L, Quarles LD,. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice. Am J Physiol Endocrinol Metab. 2007; 293: E1636-44.
37. Aono Y, Yamazaki Y, Yasutake J, et al., Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res. 2009; 24: 1879-88.
38. Wang H, Yoshiko Y, Yamamoto R, et al., Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res. 2008; 23: 939-48.
39. Sitara D, Kim S, Razzaque MS, et al., Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet. 2008; 4: e1000154.
40. Shalhoub V, Ward SC, Sun B, et al., Fibroblast growth factor 23 (FGF23) and alpha-klotho stimulate osteoblastic MC3T3.E1 cell proliferation and inhibit mineralization. Calcif Tissue Int. 2011; 89: 140-50.
41. Allard L, Demoncheaux N, Machuca-Gayet I, et al., Biphasic effects of vitamin D and FGF23 on human osteoclast biology. Calcif Tissue Int. 2015; 97: 69-79.
42. Burkhardt R, Kettner G, Bohm W, et al., Changes in trabecular bone, hematopoiesis and bone marrow vessels in aplastic anemia, primary osteoporosis, and old age: a comparative histomorphometric study. Bone. 1987; 8: 157-64.
43. Manolagas SC,. Role of cytokines in bone resorption. Bone. 1995; 17: 63S-7S.
44. Chen W, Melamed ML, Abramowitz MK,. Serum bicarbonate and bone mineral density in US adults. Am J Kidney Dis. 2015 Feb; 65 (2): 240-8.
45. Nickolas TL, Stein EM, Dworakowski E, et al., Rapid cortical bone loss in patients with chronic kidney disease. J Bone Miner Res. 2013; 28: 1811-20.